Start › Czerniak › Tennessee › Nashville
Badania kliniczne dla Czerniak w mieście Nashville, TN
33 badań dla Czerniak szuka uczestników w ośrodkach w mieście Nashville i okolicach (w promieniu ok. 30 mil). Otwórz badanie, aby zobaczyć kryteria kwalifikacji i dane kontaktowe zespołu badawczego.
Oficjalny tekst badania (angielski)
Rekrutujesz uczestników do badania? Wyróżnij je na górze tej strony – $99 za 30 dni →
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
RekrutacjaFaza 1
- Tennessee Oncology, Nashville
Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
RekrutacjaFaza 1/2
- Sarah Cannon Research Institute, Nashville
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RekrutacjaFaza 2
- SCRI Oncology Partners, Nashville
A Study of BI 3810944 in Patients With Advanced Cancer
RekrutacjaFaza 1
- Tennessee Oncology, PLLC - Elliston Place Plaza DDU, Nashville
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
RekrutacjaFaza 1
- Sarah Cannon Research Institute- Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
RekrutacjaFaza 3
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
- Tennessee Oncology, Nashville
DESTINY-PANTUMOUR04
RekrutacjaBadanie obserwacyjne
- Research Site, Nashville
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
RekrutacjaFaza 1/2
- Vanderbilt University Medical Center, Nashville
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
RekrutacjaFaza 3
- SCRI Oncology Partners, Nashville
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
RekrutacjaFaza 3
- Vanderbilt University/Ingram Cancer Center, Nashville
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
RekrutacjaFaza 1/2
- Sarah Cannon Research Institute, Nashville
R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
RekrutacjaFaza 1
- Sarah Cannon Research Institute, Nashville
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
RekrutacjaFaza 1/2
- Sarah Cannon Research Institute Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Institute, Nashville
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
RekrutacjaFaza 1
- Sarah Cannon Research Institute-Tennessee Oncology, Nashville
Project: Every Child for Younger Patients With Cancer
RekrutacjaBadanie obserwacyjne
- The Children's Hospital at TriStar Centennial, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
RekrutacjaFaza 1/2
- Vanderbilt University Medical Center, Nashville
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
RekrutacjaFaza 1/2
- Tennessee Oncology, PLLC, Nashville
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
RekrutacjaFaza 1/2
- Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
RekrutacjaFaza 1/2
- SCRI Oncology Partners, Nashville
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
RekrutacjaFaza 1
- Tennessee Oncology, Nashville
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
RekrutacjaFaza 1/2
- Sarah Cannon Research Institute, Nashville
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
RekrutacjaFaza 1/2
- The Sarah Cannon Research Institute/Tennessee Oncology, Nashville
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
RekrutacjaFaza 1/2
- Sarah Cannon Research Institute, Nashville
Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
Rekrutacja
- Vanderbilt-Ingram Cancer Center, Nashville
Neoadjuvant Darovasertib in Primary Uveal Melanoma
RekrutacjaFaza 3
- SCRI Oncology Partners, Nashville
- Vanderbilt Eye Institute, Nashville
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RekrutacjaFaza 1
- SCRI Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
RekrutacjaFaza 2/3
- Sarah Cannon Research Institute, Nashville
- Vanderbilt Ingram Cancer Center (Henry-Joyce Cancer Clinic), Nashville
Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma
RekrutacjaFaza 1
- Vanderbilt-Ingram Cancer Center, Nashville
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
RekrutacjaFaza 1/2
- Research Site 136, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekrutacjaBadanie obserwacyjne
- Massive Bio SYNERGY-AI site, Nashville
Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment
RekrutacjaBadanie obserwacyjne
- Vanderbitl-Ingram Cancer Center, Nashville
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RekrutacjaFaza 1/2
- Sarah Cannon Research Institute, Nashville
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
RekrutacjaFaza 1/2
- Verdi Oncology Tennessee, Scri Oncology Partners, Nashville
Badania dla Czerniak w innych miastach
- Houston, TX59 badań
- New York City, NY38 badań
- Los Angeles, CA34 badań
- Pittsburgh, PA31 badań
- Boston, MA26 badań
- Philadelphia, PA23 badań
- San Francisco, CA22 badań
- Columbus, OH21 badań
- Durham, NC21 badań
- Atlanta, GA21 badań
- Salt Lake City, UT21 badań
- St. Louis, MO21 badań
Inne badania w mieście Nashville
- Niedrobnokomórkowy rak płuca97 badań
- Rak piersi81 badań
- Nowotwór przerzutowy70 badań
- Rak jelita grubego i odbytnicy69 badań
- Nowotwory (wszystkie typy)65 badań
- Rak jajnika49 badań
- Rak prostaty43 badań
- Rak płuc40 badań
- Rak płaskonabłonkowy głowy i szyi39 badań
- Rak trzustki39 badań
- Rak endometrium38 badań
- Szpiczak mnogi32 badań
Źródło: ClinicalTrials.gov, dane pobrane 6 paź 2026. Każde badanie ustala własne kryteria kwalifikacji; zespół badawczy decyduje, kto może wziąć udział.